pan-genotype HCV NS3/4A protease inhibitor

proj. oral QD dosing, well-tolerated in rodent

deuteration reduced CYP TDI

J. Med. Chem., Nov. 23, 2020

Bristol-Myers Squibb, NJ + MA + CT + IN

BMS-986144

Bristol-Myers Squibb (BMS) pan-genotype HCV NS3/4A protease inhibitor


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: